Bio-Bridge's HIV vaccine exhibits no side effects during animal study

By Angela McDaniels

Seattle, Feb. 1 - Bio-Bridge Science Inc. said its HIV therapeutic vaccine (HIV-PV pseudovirus) did not have any side effects on the central nervous system, cardiovascular system or respiratory system of mice and monkeys at low, medium or high doses during recent studies.

No significant differences in blood cell and serum biochemical parameters between pre- and post-treatment groups were observed within 14 days after treatment, according to a company news release.

The vaccine targets infection in mucosal tissues, the first type of tissue attacked by HIV. It is being developed through Bio-Bridge's Beijing subsidiary and the company said it will begin clinical trials in China in the "very near future," according to the news release.

The Chinese government has implemented policies to expedite the approval of domestically produced HIV vaccines and has dramatically increased spending on AIDS-related research, according to the release.

In accordance with this policy, Bio-Bridge expects to bring its therapeutic HIV vaccine to market as early as 2008 and is constructing a $3 million research and manufacturing facility in Beijing, which will be completed in early 2006.

Bio-Bridge Science is a development-stage biotechnology firm based in Oak Brook, Ill., that develops vaccines.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.